Multidisciplinary approach to rectal cancer: Are we ready for selective treatment strategies?

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 6, 2013, Pages 852-860

  Avallone, Antonio ^a   Aloj, Luigi ^a   Delrio, Paolo ^a   Pecori, Biagio ^a   Leone, Alessandra ^a   Tatangelo, Fabiana ^a   Perri, Francesco ^a   Petrillo, Antonella ^a   Scott, Nigel ^b   Budillon, Alfredo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Chemo radiotherapy; Magnetic resonance imaging; Organ preservation; Rectal cancer; Target therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED; VASCULOTROPIN;

ADJUVANT THERAPY; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; DEATH; DISTANT METASTASIS; FECES INCONTINENCE; GENE EXPRESSION; HUMAN; INCIDENCE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN PRESERVATION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RECURRENCE RISK; SEXUAL DYSFUNCTION; TOXICITY; TREATMENT FAILURE; TUMOR GROWTH; TUMOR REGRESSION;

COMBINED MODALITY THERAPY; HUMANS; ORGAN PRESERVATION; RECTAL NEOPLASMS; RECTUM;

EID: 84880142431     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990123     Document Type: Article

References (104)

1. Avallone, A.; Delrio, P.; Aloj, L.; Di Gennaro, E.; Guida, C.; Tatangelo, F.; Petrillo, A.; Cascini, GL.; Parisi, V.; Budillon, A.; Lastoria, S.; Comella, P. Locally advanced rectal cancer: combined chemotherapy during preoperative radiation therapy. references colorectal cancer methods of cancer diagnosis, therapy, and prognosis, 2009, Volume 4, 411-436
2. Glynne-Jones, R.; Kronfli, M. Locally advanced rectal cancer: a comparison of management strategies. Drugs, 2011, 71(9), 1153-1177
3. Avallone, A.; Delrio, P. Lastoria, S.; Comella, P. Chemoradiotherapy in locally advanced rectal cancer: What is the optimal strategy? Eur. J. Cancer, 2008, 6(14), 70-73
4. Bosset, J.F.; Collette, L.; Calais, G.; Mineur, L.; Maingon, P.; Radosevic-Jelic, L.; Daban, A.; Bardet, E.; Beny, A.; Ollier, J.C. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med., 2006, 355(11), 1114-1123.
5. Gerard, J.P.; Conroy, T., Bonnetain, F.; Bouché, O.; Chapet, O.; Closon-Dejardin, M.T.; Untereiner, M.; Leduc, B.; Francois, E.; Maurel, J.; Seitz, J.F.; Buecher, B.; Mackiewicz, R.; Ducreux, M.; Bedenne, L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J. Clin. Oncol., 2006, 24(28), 4620-4625.
6. Sauer, R., Becker, H., Hohenberger, W.; Rödel, C.; Wittekind, C.; Fietkau, R.; Martus, P.; Tschmelitsch, J.; Hager, E.; Hess, C.F.; Karstens, J.H.; Liersch, T.; Schmidberger, H.; Raab, R.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med., 2004, 351(17), 1731-1740.
7. Kapiteijn, E.; Marijnen, C.A.; Nagtegaal, I.D.; Putter, H.; Steup, W.H.; Wiggers, T.; Rutten, H.J., Pahlman, L.; Glimelius, B., van Krieken, J.H., Leer, J.W., van de Velde, C.J.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med., 2001, 345(9), 638-646.
8. Sebag-Montefiore, D.; Stephens, R.J.; Steel, R.; Monson, J.; Grieve, R.; Khanna, S.; Quirke, P.; Couture, J.; de Metz, C.; Myint, A.S.; Bessell, E.; Griffiths, G.; Thompson, L.C.; Parmar, M. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicenter randomized trial. Lancet, 2009, 373 (9666), 811-820.
9. Marijnen, C.A.; van de Velde, C.J.; Putter, H.; van den Brink, M.; Maas, C.P.; Martijn, H.; Rutten, H.J.; Wiggers, T.; Kranenbarg, E.K.; Leer, J.W.; Stiggelbout, A.M. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: Report of a multicenter randomized trial. J. Clin. Oncol., 2005, 23(9), 1847-1858.
10. Peeters, K.C.; van de Velde, C.J.; Leer, J.W.; Martijn, H.; Junggeburt, J.M.; Kranenbarg, E.K.; Steup, W.H.; Wiggers, T.; Rutten, H.J.; Marijnen, C.A. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients-a Dutch colorectal cancer group study. J. Clin. Oncol., 2005, 23(25), 6199-6206.
11. Bujko, K.; Nowacki, M.P.; Nasierowska-Guttmejer, A.; Michalski, W.; Bebenek, M.; Kryj, M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br. J. Surg., 2006, 93(10), 1215-23.
12. Ngan, S.; Fisher, R.; Goldstein, D.; Solomon, M.; Burmeister, B.; Ackland, S.P.; Joseph, D.J.; McClure, B.; McLachlan, S.; MackayJ. A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC)preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS). J. Clin. Oncol., 2010, 28, suppl.15, (abstract 3509).
13. Valentini, V.; van Stiphout, R.G.; Lammering, G.; Gambacorta, M.A.; Barba, M.C.; Bebenek, M.; Bonnetain, F.; Bosset, J.F.; Bujko, K.; Cionini, L.; Gerard, J.P.; Rödel, C.; Sainato, A., Sauer, R.; Minsky, B.D.; Collette, L.; Lambin, P. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J. Clin. Oncol., 2011, 29(23), 3163-3172
14. Fiorica, F.; Cartei, F.; Licata, A.; Enea, M.; Ursino, S.; Colosimo, C.; Cammà, C. Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treat. Rev., 2010, 36(7), 539-549.
15. Braendengen, M.; Tveit, K.M.; Berglund, A.; Birkemeyer, E.; Frykholm, G.; Påhlman, L.; Wiig, J.N.; Byström, P.; Bujko, K.; Glimelius, B. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J. Clin. Oncol., 2008, 26(22), 3687-3694.
16. Braendengen, M.; Tveit, K.M.; Bruheim, K.; Cvancarova, M.; Berglund, A.; Glimelius, B. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: Results from a randomized Phase III study. Int. J. Radiat. Oncol. Biol. Phys., 2011, 81(4), 1017-1024.
17. Glynne-Jones, R. The future of rectal cancer: Let's do the right trials. J. Clin. Oncol., 2011, 29(30), 4057-4059.
18. Gunderson, L.L.; Sargent, D.J.; Tepper, J.E.; Wolmark, N.; O'Connell, M.J.; Begovic, M.; Allmer, C.; Colangelo, L.; Smalley, S.R.; Haller, D.G.; Martenson, J.A.; Mayer, R.J.; Rich, T.A.; Ajani, J.A.; MacDonald, J.S.; Willett, C.G.; Goldberg, R.M. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis. J. Clin. Oncol., 2004, 22(10), 1785-1796.
19. Merkel, S.; Mansmann, U.; Siassi, M.; Papadopoulos, T.; Hohenberger, W.; Hermanek P. The prognostic inhomogeneity in pT3 rectal carcinomas. Int. J. C. Colorectal. Dis., 2001, 16(5), 298-304.
20. Nagtegaal, I.D.; Gosens, M.J.; Marijnen, C.A.; Rutten, H.J.; van de Velde, C.J.; van Krieken, J.H. Combinations of tumor and treatment parameters are more discriminative for prognosis than the present TNM system in rectal cancer. J. Clin. Oncol., 2008, 25(13), 1647-1650.
21. Nagtegaal, I.D.; van de Velde, C.J.; Marijnen, C.A.; van Krieken, J.H., Quirke, P. Low rectal cancer: A call for a change of approach in abdominoperineal resection. J. Clin. Oncol., 2005, 23(36), 9257-9264.
22. Marijnen, C.A.; Nagtegaal, I.D.; Kapiteijn, E.; Kranenbarg, E.K.; Noordijk EM, van Krieken, J.H., van de Velde, C.J.; Leer, J.W. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: Report of a multicenter randomized trial. Int. J. Radiat. Oncol. Biol. Phys., 2003, 55(5), 1311-1320.
23. Mercury Study Group. Diagnostic accurancy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: Prospective observation study. BMJ, 2007, 333(7572), 779-784.
24. Burton, S.; Brown, G.; Daniels, I.R.; Norman, A.R.; Mason, B.; Cunningham, D. MRI directed multidisciplinary team preoperative treatment strategy: The way to eliminate positive circumferential margins? Br. J. Cancer, 2006, 94(3), 351-357.
25. Frasson, M.; Garcia-Granero, E.; Roda, D.; Flor-Lorente, B.; Roselló, S.; Esclapez, P.; Faus, C.; Navarro, S.; Campos, S.; Cervantes, A. Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. Cancer, 2011, 117(14), 3118-3125.
26. Gimelius, B.; Beets-Tan, R.; Blomqvist, L.; Brown, G.; Nagtegaal, I.; Påhlman, L.; Quirke, P.; Valentini, V.; van de Velde, C. Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J. Clin. Oncol., 2011, 29(16), 2142-2143.
27. Guillem, J.G.; Díaz-González, J.A.; Minsky, B.D.; Valentini, V.; Jeong, S.Y.; Rodriguez-Bigas, M.A.; Coco, C.; Leon, R.; Hernandez-Lizoain, J.L.; Aristu, J.J.;, Riedel, E.R.; Nitti, D.; Wong, W.D.; Pucciarelli, S. cT3N0 rectal cancer: Potential overtreatment with preoperative chemoradiotherapy is warranted. J. Clin. Oncol., 2008, 26(3), 368-373.
28. Mehta, V.K.; Cho, C.; Ford, J.M.; Jambalos, C.; Poen, J.; Koong, A., Lin, A.; Bastidas, J.A.; Young, H.; Dunphy, E.P.; Fisher, G. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys., 2003, 55(1), 132-137.
29. Rodel, C.; Grabenbauer, G.G.; Papadopoulos, T.; Hohenberger, W.; Schmoll, H.J.; Sauer, R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J. Clin. Oncol., 2003, 21(16), 3098-3104.
30. Aschele, C.; Friso, M.L.; Pucciarelli, S.; Lonardi, S.; Sartor, L.; Fabris, G.; Urso, E.D.; Del Bianco, P.; Sotti, G.; Lise, M.; Monfardini, S. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann. Oncol., 2005, 16(7), 1140-1146.
31. Avallone, A.; Delrio, P.; Guida, C.; Tatangelo, F.; Petrillo, A.; Marone, P.; Cascini, L.G.; Morrica, B.; Lastoria, S.; Parisi, V.; Budillon, A.; Comella, P. Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: A phase I-II study. Br. J. Cancer, 2006, 94(12), 1809-1815.
32. Glynne-Jones, R.; Falk, S.; Maughan, T.S.; Meadows, H.M.; Sebag-Montefiore, D. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: A Colorectal Clinical Oncology Group Study. Br. J. Cancer, 2007, 96(4), 551-558.
33. Wong, S.J.; Winter, K.; Meropol, N.J.; Anne, P.R.; Kachnic, L.; Rashid, A.; Watson, J.C.; Mitchell, E.; Pollock, J.; Lee, R.J.; Haddock, M.; Erickson, B.A.; Willett, C.G. Radiation Therapy Oncology Group 0247: A randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys., 2012, 82, 1367-1375.
34. Gérard, J.P.; Azria, D.; Gourgou-Bourgade, S.; Martel-Laffay, I.; Hennequin, C.; Etienne, P.L.; Vendrely, V.; François, E.; de La Roche, G.; Bouché, O.; Mirabel, X.; Denis, B.; Mineur, L.; Berdah, J.F.; Mahé, M.A.; Bécouarn, Y.; Dupuis, O.; Lledo, G.; Montoto-Grillot, C.; Conroy, T. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J. Clin. Oncol., 2010, 28(10), 1638-1644.
35. Aschele, C.; Cionini, L., Lonardi, S.; Pinto, C.; Cordio, S.; Rosati, G.; Artale, S.; Tagliagambe, A.; Ambrosini, G.; Rosetti, P.; Bonetti, A.; Negru, M.E.; Tronconi, M.C.; Luppi, G.; Silvano, G.; Corsi, D.C.; Bochicchio, A.M.; Chiaulon, G.; Gallo, M.; Boni, L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J. Clin. Oncol., 2011, 29(20), 2773-2780
36. Avallone, A.; Delrio, P.; Pecori, B.; Tatangelo, F.; Petrillo, A.; Scott, N.; Marone, P.; Aloi, L.; Sandomenico, C.; Lastoria, S.; Iaffaioli, V.R.; Scala, D.; Iodice, G.; Budillon, A.; Comella, P. Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: Long-term outcome. Int. J. Radiat. Oncol. Biol. Phys., 2011, 79(3), 670-676.
37. Roedel, C.; Becker, H.; Fietkau, R.; Graeven, U.; Hohenberger, W.; Hothorn, T.; Lang-Welzenbach, M.; Liersch, T.; Staib, L.; Christiansen, H.; Wittekind, C.; Sauer, R. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol., 2012, 13(7), 679-687.
38. Glynne-Jones, R.; Anyamene, N.; Moran, B.; Harrison, M. Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation? Ann. Oncol., 2012, Feb 23. Epub ahead of print
39. Fernández-Martos, C.; Pericay, C.; Aparicio, J.; Salud, A.; Safont, M.; Massuti, B.; Vera, R.; Escudero, P.; Maurel, J.; Marcuello, E.; Mengual, J.L.; Saigi, E.; Estevan, R.; Mira, M.; Polo, S.; Hernandez, A.; Gallen, M.; Arias, F.; Serra, J.; Alonso, V. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imagingdefined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J. Clin. Oncol., 2010, 28(5), 859-865.
40. Maréchal, R.; Vos, B.; Polus, M.; Delaunoit, T.; Peeters, M.; Demetter, P.; Hendlisz, A.; Demols, A.; Franchimont, D.; Verset, G.; Van Houtte, P.; Van de Stadt, J.; Van Laethem, J.L. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: A randomized multicentric phase II study. Ann. Oncol., 2012, 23(6), 1525-1530.
41. Chau, I.; Brown, G.; Cunningham, D.; Tait, D.; Wotherspoon, A.; Norman, A.R.; Tebbutt, N.; Hill, M.; Ross, P.J.; Massey, A.; Oates, J. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J. Clin. Oncol., 2006, 24(4), 668-674.
42. Tulchinsky, H.; Shmueli, E.; Figer, A.; Klausner, J.M.; Rabau, M. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann. Surg. Oncol., 2008, 15(10), 2661-2667.
43. Kalady, M.F.; de Campos-Lobato, L.F.; Stocchi, L.; Geisler, D.P.; Dietz, D.; Lavery, I.C.; Fazio, V.W. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann. Surg., 2009, 250(4), 582-589.
44. Hatfield, P; Hingorani, M; Radhakrishna, G; Cooper, R; Melcher, A; Crellin, A.; Kwok-Williams, M.; Sebag-Montefiore. D. Shortcourse radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother. Oncol., 2009, 92(2), 210-214.
45. Radu, C.; Berglund, A.; Påhlman, L.; Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer-A retrospective study. Radiother. Oncol., 2008, 87(3), 343-349.
46. Habr-Gama, A.; Perez, R.O.; Sabbaga, J.; Nadalin, W.; São Julião, G.P.; Gama-Rodrigues, J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: Results of a prospective study using additional chemotherapy during the resting period. Dis. Colon Rectum, 2009, 52(12), 1927-1934.
47. Garcia-Aguilar, J.; Smith, D.D.; Avila, K.; Bergsland, E.K.; Chu, P.; Krieg, R.M. Optimal timing of surgery after chemoradiation for advanced rectal cancer: Preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann. Surg., 2011, 254(1), 97-102.
48. Schrag, D.; Weiser, M. R.; Goodman, K. A.; Reidy, D.L.; Cercek, A.; Gonen, M.; Wong, W.D.; Temple, L.K.; Paty, P.; Saltz, L. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. J. Clin. Oncol., 2010, 28, abstr 3511.
49. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350(23), 2335-2342.
50. Van Cutsem, E.; Köhne, C.H.; Hitre, E.; Zaluski, J.; Chang Chien, C.R.; Makhson, A.; D'Haens, G.; Pintér, T.; Lim, R.; Bodoky, G.; Roh, J.K.; Folprecht, G.; Ruff, P.; Stroh, C.; Tejpar, S.; Schlichting, M.; Nippgen, J.; Rougier, P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med., 2009, 360(14), 1408-1417.
51. Douillard, J.Y.; Siena, S.; Cassidy, J.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; Rivera, F.; Kocákova, I.; Ruff, P.; Błasińska-Morawiec, M.; Bmakal, M.; Canon, J.L.; Rother, M.; Oliner, K.S.; Wolf, M.; Gansert, J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J. Clin. Oncol., 2010, 28(31), 4697-4705.
52. Giralt, J.; de las Heras, M.; Cerezo, L.; Eraso, A.; Hermosilla, E.; Velez, D.; Lujan, J.; Espin, E.; Rosello, J.; Majó, J.; Benavente, S.; Armengol, M.; de Torres, I. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: A multicenter, retrospective analysis. Radiother. Oncol., 2005, 74(2), 101-108.
53. Kim, J.S.; Kim, J.M.; Li, S.; Yoon, W.H.; Song, K.S.; Kim, K.H.; Yeo, S.G.; Nam, J.S.; Cho, M.J. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2006, 66(1), 195-200.
54. Baumann, M.; Krause, M.; Dikomey, E.; Dittmann, K.; Dörr, W.; Kasten-Pisula, U.; Rodemann, H.P. EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiother. Oncol., 2007, 83(3), 238-248.
55. Glynne-Jones, R.; Mawdsley, S.; Harrison, M. Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? Acta Oncol., 2010, 49(3), 278-286.
56. Debucquoy, A.; Haustermans, K.; Daemen, A.; Aydin, S.; Libbrecht, L.; Gevaert, O.; De Moor, B.; Tejpar, S.; McBride, W.H.; Penninckx, F.; Scalliet, P.; Stroh, C.; Vlassak, S.; Sempoux, C.; Machiels, J.P. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J. Clin. Oncol., 2009, 27(17), 2751-2757.
57. Grimminger, P.P.; Danenberg, P.; Dellas, K.; Arnold, D.; Rödel, C.; Machiels, J.P.; Haustermans, K.; Debucquoy, A.; Velenik, V.; Sempoux, C.; Bracko, M.; Hölscher, A.H.; Semrau, R.; Yang, D.; Danenberg, K.; Lenz, H.J.; Vallböhmer, D. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin. Cancer Res., 2011, 17(10), 3469-3477.
58. Hu-Lieskovan, S.; Vallbohmer, D.; Zhang, W.; Yang, D.; Pohl, A.; Labonte, M.J.; Grimminger, P.P.; Hölscher, A.H.; Semrau, R.; Arnold, D.; Dellas, K.; Debucquoy, A.; Haustermans, K.; Machiels, J.P.; Sempoux, C.; Rödel, C.; Bracko, M.; Velenik, V.; Lenz, H.J. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin. Cancer Res., 2011, 17(15), 5161-5169.
59. Dewdney, A.; Cunningham, D.; Tabernero, J.; Capdevila, J.; Glimelius, B.; Cervantes, A.; Tait, D.; Brown, G.; Wotherspoon, A.; Gonzalez de Castro, D.; Chua, Y.J.; Wong, R.; Barbachano, Y.; Oates, J.; Chau, I. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin. Oncol., 2012, 30(14), 1620-1627.
60. Maughan, T.S.; Adams, R.A.; Smith, C.G.; Meade, A.M.; Seymour, M.T.; Wilson, R.H.; Idziaszczyk, S.; Harris, R.; Fisher, D.; Kenny, S.L.; Kay, E.; Mitchell, J.K.; Madi, A.; Jasani, B.; James, M.D.; Bridgewater, J.; Kennedy, M.J.; Claes, B.; Lambrechts, D.; Kaplan, R.; Cheadle, J.P. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet, 2011, 377(9783), 2103-2014.
61. Tveit, K.M.; Guren, T.; Glimelius, B.; Pfeiffer, P.; Sorbye, H.; Pyrhonen, S.; Sigurdsson, F.; Kure, E.; Ikdahl, T.; Skovlund, E.; Fokstuen, T.; Hansen, F.; Hofsli, E.; Birkemeyer, E.; Johnsson, A.; Starkhammar, H.; Yilmaz, M.K.; Keldsen, N.; Erdal, A.B.; Dajani, O.; Dahl, O.; Christoffersen, T. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. J Clin Oncol., 2012, 30(15), 1755-1762.
62. Kozin, S.V.; Boucher, Y.; Hicklin, D.J.; Bohlen, P.; Jain, R.K.; Suit, H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res., 2001, 61(1), 39-44.
63. Cascinu, S.; Graziano, F.; Catalano, V.; Staccioli, M.P.; Rossi, M.C.; Baldelli, A.M.; Barni, S.; Brenna, A.; Secondino, S.; Muretto, P.; Catalano, G. An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. Br. J. Cancer, 2002, 86(5), 744-749.
64. Willett, C.G.; Boucher, Y.; di Tomaso, E.; Duda, D.G.; Munn, L.L.; Tong, R.T.; Chung, D.C.; Sahani, D.V.; Kalva, S.P.; Kozin, S.V.; Mino, M.; Cohen, K.S.; Scadden, D.T.; Hartford, A.C.; Fischman, A.J.; Clark, J.W.; Ryan, D.P.; Zhu, A.X.; Blaszkowsky, L.S.; Chen, H.X.; Shellito, P.C.; Lauwers, G.Y.; Jain, R.K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med., 2004, 10(2), 145-147.
65. Wadlow, R.C.; Ryan, D.P. The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer, 2010, 116(15), 3537-3548.
66. Crane, C.H.; Eng, C.; Feig, B.W.; Das, P.; Skibber, J.M.; Chang, G.J.; Wolff, R.A.; Krishnan, S.; Hamilton, S.; Janjan, N.A.; Maru, D.M.; Ellis, L.M.; Rodriguez-Bigas, M.A. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys., 2010, 76(3), 824-830.
67. Dipetrillo, T.; Pricolo, V.; Lagares-Garcia, J.; Vrees, M.; Klipfel, A.; Cataldo, T.; Sikov, W.; McNulty, B.; Shipley, J.; Anderson, E.; Khurshid, H.; Oconnor, B.; Oldenburg, N.B.; Radie-Keane, K.; Husain, S.; Safran, H. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys., 2012, 82(1), 124-9.
68. Nogué, M.; Salud, A.; Vicente, P.; Arriví, A.; Roca, J.M.; Losa, F.; Ponce, J.; Safont, M.J.; Guasch, I.; Moreno, I.; Ruiz, A.; Pericay, C. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: The AVACROSS study. Oncologist, 2011, 16(5), 614-620.
69. Avallone, A.; Di Gennaro, E.; Delrio, P.; Aloj, L.; Tatangelo, F.; Pecori, B.; Leone, A.; Caracò, C.; Moccia, T.; Iaffaioli, V.R.; Romano, G.; Lastoria, S.; Budillon, A. Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab scheduleplus chemoradiation therapy in rectal cancer: Efficacy, safety, and biomarkers. AACR meeting, 2012, abstr LB219.
70. Willett, C.G.; Duda, D.G.; di Tomaso, E.; Boucher, Y.; Ancukiewicz, M.; Sahani, D.V.; Lahdenranta, J.; Chung, D. C; Fischman, A.J.; Lauwers, G.Y.; Shellito, P.C.; Czito, B.G.; Wong, T.Z.; Paulson, E.; Poleski, M.; Vujaskovic, Z.; Bentley, R.; Chen, H.X.; Clark, J.W.; Jain, R.K. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J. Clin. Oncol., 2009, 27(18), 3020-3026.
71. Allegra, C.J.; Yothers, G.; O'Connell, M.J.; Sharif, S.; Petrelli, N.J.; Colangelo, L.H.; Atkins, J.N.; Seay, T.E.; Fehrenbacher, L.; Goldberg, R.M.; O'Reilly, S.; Chu, L.; Azar, C.A.; Lopa, S.; Wolmark, N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J. Clin. Oncol., 2011, 29(1), 11-16.
72. Goldberg, R.M.; Sargent, D.J.; Thibodeau, S.N.; Mahoney, M.R.; Shields, A.F.; Chan, E.; Gill, S.; Kahlenberg, M.S.; Nair, S.; Alberts, S.R. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. J. Clin. Oncol., 2010, 28, abstr 3508.
73. Mohiuddin, M.; Mohiuddin, M.M. Neoadjuvant chemoradiotherapy in rectal cancer: Time to start in a new direction. J. Clin. Oncol., 2011, 29(12), 350-351.
74. Paun, B.C.; Cassie, S.; MacLean, A.R.; Dixon, E.; Buie, W.D. Postoperative complications following surgery for rectal cancer. Ann. Surg., 2010, 251(5), 807-818.
75. Guren, M.G.; Eriksen, M.T.; Wiig, J.N.; Carlsen, E.; Nesbakken, A.; Sigurdsson, H.K.; Wibe, A.; Tveit, K.M.; Norwegian Rectal Cancer Group. Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer. Eur. J. Surg. Oncol., 2005, 31(7), 735-742.
76. You, Y.N. Local excision: Is it an adequate substitute for radical resection in T1/T2 patients? Semin. Radiat. Oncol., 2011, 21(3), 178-184.
77. Glynne-Jones, R.; Hughes, R. Critical appraisal of the "wait and see" approach in rectal cancer for clinical complete responders after chemoradiation. Br. J. Surg., 2012, 99(7), 897-909.
78. Cascini, G.L.; Avallone, A.; Delrio, P.; Guida, C.; Tatangelo, F.; Marone, P.; Aloj, L.; De Martinis, F.; Comella, P.; Parisi, V.; Lastoria, S. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J. Nucl. Med., 2006, 47(8), 1241-1248.
79. Avallone, A.; Aloj, L.; Caracò, C.; Delrio, P.; Pecori, B.; Tatangelo, F.; Scott, N.; Casaretti, R.; Di Gennaro, F.; Montano, M.; Silvestro, L.; Budillon, A.; Lastoria, S. Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: Correlation with long-term outcome. Eur. J. Nucl. Med. Mol. Imag., 2012, Oct 5. Epub ahead of print.
80. Patel, U.B.; Taylor, F.; Blomqvist, L.; George, C.; Evans, H.; Tekkis, P.; Quirke, P.; Sebag-Montefiore, D.; Moran, B.; Heald, R.; Guthrie, A.; Bees, N.; Swift, I.; Pennert, K.; Brown, G. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J. Clin. Oncol., 2011, 29(28), 3753-60.
81. Rectal cancer V.3. NCCN Clinical Practical Guidelines in Oncology 2012; http://www.nccn.org/professionals/physician_gls/f_guidelines. asp#site
82. Bujko, K.; Glynne-Jones, R.; Bujko, M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann. Oncol., 2010, 21(9), 1743-1750.
83. Andrè, T.; Boni, C.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Bonetti, A.; Clingan, P.; Bridgewater, J.; Rivera, F.; de Gramont, A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol., 2009, 27(19), 3109-3116.
84. Kuebler, J.P.; Wieand, H.S.; O'Connell, M.J.; Smith, R.E.; Colangelo, L.H.; Yothers, G.; Petrelli, N.J.; Findlay, M.P.; Seay, T.E.; Atkins, J.N.; Zapas, J.L.; Goodwin, J.W.; Fehrenbacher, L.; Ramanathan, R.K.; Conley, B.A.; Flynn, P.J.; Soori, G.; Colman, L.K.; Levine, E.A.; Lanier, K.S.; Wolmark, N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J. Clin. Oncol., 2007, 25(16), 2198-2204.
85. QUASAR Collaborative Group, Gray, R.; Barnwell, J.; McConkey, C.; Hills, R.K.; Williams, N.S.; Kerr, D.J. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomized study. Lancet, 2007, 370, 2020-2029.
86. Kalady, M.F.; Sanchez, J.A.; Manilich, E.; Hammel, J.; Casey, G.; Church, J.M. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis. Colon Rectum, 2009, 52(6), 1039-1045
87. Hong, T.S.; Clark, J.W.; Haigis, K.M. Cancers of the colon and rectum: Identical or fraternal twins? Cancer Discovery, 2012, 2(2), 117-121
88. Rodel, C.; Martus, P.; Papadoupolos, T.; Füzesi, L.; Klimpfinger, M.; Fietkau, R.; Liersch, T.; Hohenberger, W.; Raab, R.; Sauer, R.; Wittekind, C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J. Clin. Oncol., 2005, 23(34), 8688-8696.
89. Bujko, K.; Michalski, WMS.; Kepka, L.; Nowacki, M.P.; Nasierowska-Guttmejer, A.; Tokar, P.; Dymecki, D.; Pawlak, M.; Lesniak, T.; Richter, P.; Wojnar, A.; Chmielik, E. Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial. Int. J. Radiat. Oncol. Biol. Phys., 2007, 67(2), 369-377.
90. Fietkau, R.; Barten, M.; Klautke, G.; Klar, E.; Ludwig, K.; Thomas, H.; Brinckmann, W.; Friedrich, A.; Prall, F.; Hartung, G.; Küchenmeister, U.; Kundt G. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis. Colon Rectum, 2006, 49(9), 1284-1292.
91. Leibold, T.; Shia, J.; Ruo, L.; Minsky, B.D.; Akhurst, T.; Gollub, M.J.; Ginsberg, M.S.; Larson, S.; Riedel, E.; Wong, W.D.; Guillem, J.G. Prognostic implication of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy. J. Clin. Oncol., 2008, 26(13), 2106-2111.
92. Mawdsley, S.; Glynne-Jones, R.; Grainger, J.; Richman, P.; Makris, A.; Harrison, M.; Ashford, R.; Harrison, R.A.; Osborne, M.; Livingstone, J.I.; MacDonald, P.; Mitchell, I.C.; Meyrick-Thomas, J.; Northover, J.M.; Windsor, A.; Novell, R.; Wallace, M. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int. J. Radiat. Oncol. Biol. Phys., 2005, 63(3), 745-752.
93. Capirci, C.; Valentini, V.; Cionini, l.; De Paoli, A.; Rodel, C.; Glynne-Jones, R.; Coco, C.; Romano, M.; Mantello, G.; Palazzi, S.; Mattia, F.O.; Friso, M.L.; Genovesi, D.; Vidali, C.; Gambacorta, M.A.; Buffoli, A.; Lupattelli, M.; Favretto, M.S.; La Torre, G. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: Long-term analysis of 566 ypCR patients. Int. J. Radiat. Oncol. Biol. Phys., 2008, 72(1), 99-107.
94. Maas, M.; Nelemans, P.J.; Valentini, V.; Das, P.; Rödel, C.; Kuo, L.J.; Calvo, F.A.; García-Aguilar, J.; Glynne-Jones, R.; Haustermans, K.; Mohiuddin, M.; Pucciarelli, S.; Small, W. Jr; Suárez, J.; Theodoropoulos, G.; Biondo, S.; Beets-Tan, R.G.; Beets, G.L. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol., 2010, 11(9), 835-844.
95. Park, I.J.; You, N.; Agarwal, A.; Skibber, J.M.; Rodriguez-Bigas, M.A.; Eng, C.; Feig, B.W.; Das, P.; Krishnan, S.; Crane, C.H.; Hu, C.Y.; Chang, G.J. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J. Clin. Oncol., 2012, 30(15), 1770-1776.
96. de Campos-Lobato, L.F.; Stocchi, L.; da Luz Moreira, A.; Kalady, M.F.; Geisler, D.; Dietz, D.; Lavery, I.C.; Remzi, F.H.; Fazio, V.W. Downstaging without complete pathologic response after neoadjuvant treatment improvescancer outcomes for cIII but not cII rectal cancers. Ann. Surg. Oncol., 2010, 17(7), 1758-1766.
97. Mandard, A.M.; Dalibard, F.; Mandard, J.C.; Marnay, J.; Henry-Amar, M.; Petiot, J.F.; Roussel, A.; Jacob, J.H.; Segol, P.; Samama, G. Pathologic assessmentof tumor regression grade after preoperative chemoradiotherapy of esophageal carcinoma: Clinicopathologiccorrelations. Cancer, 1994, 73(11), 2680-2686.
98. rd; Cummings, B.; Gunderson, L.; Macdonald, J.S.; Mayer, R.J. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J. Clin. Oncol., 2001, 19(1), 157-163.
99. Nagtegaal, I.D.; van de Velde, C.J.; van der Worp, E.; Kapiteijn, E.; Quirke, P.; van Krieken, J.H. Macroscopic evaluation of rectal cancer resection specimen: Clinical significance of the pathologist in quality control. J. Clin. Oncol., 2002, 20(7), 1729-1734.
100. Quirke, P.; Steele, R.; Monson, J.; Grieve, R.; Khanna, S.; Couture, J.; O'Callaghan, C.; Myint, A.S.; Bessell, E.; Thompson, L.C.; Parmar, M.; Stephens, R.J.; Sebag-Montefiore, D. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: A prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet, 2009, 373(9666), 821-828.
101. Fiorica, F.; Cartei, F.; Carau, B.; Berretta, S.; Spartà, D.; Tirelli, U.; Santangelo, A.; Maugeri, D.; Luca, S.; Leotta, C.; Sorace, R.; Berretta, M. Adjuvant radiotherapy on older and oldest elderly rectal cancer patients. Arch. Gerontol. Geriatr., 2009, 49(1), 54-59.
102. Ghadimi, B.M.; Grade, M.; Difilippantonio, M.J.; Varma, S.; Simon, R.; Montagna, C.; Füzesi, L.; Langer, C.; Becker, H.; Liersch, T.; Ried, T. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J. Clin. Oncol., 2005, 23(9), 1826-1838.
103. Watanabe, T.; Komuro, Y.; Kiyomatsu, T.; Kanazawa, T.; Kazama, Y.; Tanaka, J.; Tanaka, T.; Yamamoto, Y.; Shirane, M.; Muto, T.; Nagawa, H. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy byDNA microarray analysis of gene expression profiles. Cancer Res., 2006, 66(7), 3370-3374.
104. Brettingham-Moore, K.H.; Duong, C.P.; Greenawalt, D.M.; Heriot, A.G.; Ellul, J.; Dow, C.A.; Murray, W.K.; Hicks, R.J.; Tjandra, J.; Chao, M.; Bui, A.; Joon, D.L.; Thomas, R.J.; Phillips, W.A. Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma. Clin. Cancer Res., 2011, 17(9), 3039-3047.